| Abstrakt: |
ABSTRACTThe in vitro activity of LY333328 was evaluated for 1,479 nosocomial gram-positive pathogens isolated in 12 countries during 1997. LY333328 MICs at which 90% of the isolates tested were inhibited for Enterococcus faecalis(n= 351),Enterococcus faecium(n= 100),Staphylococcus aureus(n= 593), coagulase-negative Staphylococcusspecies (n= 325), and Streptococcus pneumoniae(n= 110) were 1, 1, 2, 2, and 0.015 μg/ml, respectively. LY333328 demonstrated potent activity against isolates of vancomycin-resistant enterococci, oxacillin-resistant staphylococci, and penicillin-resistant pneumococci. |
